Loading…
Generic Drug Pricing Fairness Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
37pct
2d open
vs 5,821 other HR bills in the 113th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (8)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2014 · fourth_quarter · Pharmacy
Issues related to prescription drug abuse, pharmacist provider status, drug pricing and drug supply chain safety.HR 3204 Drug Quality and Security Act HR 4069-Ensuring Patient Access and Effective Drug Enforcement Act of 2013 S 2862-Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 HR 4190-Medicare Patient Access to Pharmacist Services in Medically Underserved Communities HR 4437- Generic Drug Pricing Fairness Act of 2014 HR 4709-Ensuring Patient Access and Effective Drug Enforcement Acot of 2013 S. 1493-Medicare Efficient Drug Dispensing Act of 2013
Client expense: $3,810,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2014 · fourth_quarter · Medicare/Medicaid
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General legislative and regulatory issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales price. Medicare audit and preferred network restrictions. S. 867, HR 4437, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock in, etc.).
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · fourth_quarter · Pharmacy
Policies related to FEHBP's pharmacy benefit (HR 1367). Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR. Specialty pharmacy tiering restrictions (HR 460). Regulatory implementation of a pathway for the approal of biosimilars. REMs. 340b program reform. Policies placing restrictions on pharmcy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act). S. 867, HR 4437, HR 4577.
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · fourth_quarter · Pharmacy
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, S. 3004 Dormant Therapies Act, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation
Client expense: $750,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · fourth_quarter · Pharmacy
S.644, Preventing Abuse of Cough Treatments Act of 2013 S. 621, Safe Prescribing Act of 2013 H.R. 1285, Safe Prescribing Act of 2013 H.R. 1919 Safeguarding America's Pharmaceuticals Act of 2013 S 959, Pharmaceutical Compounding Quality and Accountability Act S 1277, Combating Prescription Drug Abuse Act S.957, Drug Supply Chain Security Act H.R.3204 - Drug Quality and Security Act H.R. 4437 - Generic Drug Pricing Fairness Act
Client expense: $460,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · fourth_quarter · Pharmacy
H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; S. 557 Medication Therapy Empowerment Act of 2013; H.R. 1188- The Preserving Our Hometown Independent Pharmacies Act of 2013; CMS proposed and final rule on Medicare Part D; H.R. 4709- Ensuring Patient Access and Effective Drug Enforcement Act of 2014; S.2862 - Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014; H.R. 4190- To Amend Title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services; FDAs action on and enforcement of Public Law No: 113-54; H.R.4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014; H.R.4437 - Generic Drug Pricing Fairness Act; S. 1493 - Medicare Efficient Drug Dispensing Act of 2013; Generic Drug Pricing Spikes; The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013; H.R..3979 Carl Levin and Howard P. Buck Mckeon National Defense Authorization Act for Fiscal Year 2015 (Tricare Provisions); Prescription Drug Abuse and Diversion; H.R. Res. 130-FY 2015 Continuing Resolution (though December 14, 2014); H.J. Res. 291- Making Further Continuing Appropriations for Fiscal Year 2015, And For Other Purposes (Until December 17, 2014); H.R.83 - FY2015 Omnibus; Consolidated and Further Continuing Appropriations Act; H.R. 4709 - Ensuring Patient Access and Effective Drug Enforcement Act of 2014;
Client expense: $420,000 · Firm income: Not reported
2014 · fourth_quarter · Health Issues
FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; Proposed FDA rule, "Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products," RIN: 0910-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics; Implementation of Biosimilars in the Affordable Care Act (ACA), Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act; H.R. 4437, The Generic Drug Pricing Transparency Act, Generic drug pricing issues, Medicare Part D program and Generic Drugs; H.R. 5657, the Fair Access for Safe and Timely Generics Act of 2014 (FAST Generics Act) PEPFAR program supply chain management
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Prescription Drug Abuse. Support of the Alliance to Prevent the Abuse of Medicines legislative priorities including minimum requirements for state databases, pharmacy lock-in programs, and abuse deterrent technology. Biosimilars - concerns regarding naming (shared names with reference product vs. original names); specialty drug cost trends HR 4577 Ensuring Seniors Access to Local Pharmacies Act - opposed HR 460 Patients Access to Treatment Act - opposed HR 4437 Medication Therapy Empowerment Act - oppose expanding to one condition
Client expense: $250,000 · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2014 · fourth_quarter · Pharmacy
Prescription Drug Abuse. Support of the Alliance to Prevent the Abuse of Medicines legislative priorities including minimum requirements for state databases, pharmacy lock-in programs, and abuse deterrent technology. Biosimilars - concerns regarding naming (shared names with reference product vs. original names); specialty drug cost trends HR 4577 Ensuring Seniors Access to Local Pharmacies Act - opposed HR 460 Patients Access to Treatment Act - opposed HR 4437 Medication Therapy Empowerment Act - oppose expanding to one condition
Client expense: $250,000 · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2014 · third_quarter · Pharmacy
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Client expense: $500,000 · Firm income: Not reported
2014 · third_quarter · Medicare/Medicaid
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Client expense: $500,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · third_quarter · Pharmacy
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Generic Drugs Savings, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, Issues Regarding Market Exclusivity
Client expense: $700,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2014 · third_quarter · Pharmacy
S.644, Preventing Abuse of Cough Treatments Act of 2013 S. 621, Safe Prescribing Act of 2013 H.R. 1285, Safe Prescribing Act of 2013 H.R. 1919 Safeguarding America's Pharmaceuticals Act of 2013 S 959, Pharmaceutical Compounding Quality and Accountability Act S 1277, Combating Prescription Drug Abuse Act S.957, Drug Supply Chain Security Act H.R.3204 - Drug Quality and Security Act H.R. 4437 - Generic Drug Pricing Fairness Act
Client expense: $480,000 · Firm income: Not reported
2014 · third_quarter · Health Issues
Federal policy regarding Public Law 113-54, the Drug Quality and Security Act; FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; Proposed FDA rule, "Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products," RIN: 0910-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics; Implementation of Biosimilars in the Affordable Care Act (ACA), Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act; The Generic Drug Pricing Transparency Act, H.R. 4437; Risk Evaluation Mitigation Strategies, Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; The Fair Access for Safe and Timely (FAST) Generics Act. PEPFAR program supply chain management
Client expense: $230,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2014 · third_quarter · Health Issues
H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; S. 557 Medication Therapy Empowerment Act of 2013; H.R. 1188- The Preserving Our Hometown Independent Pharmacies Act of 2013; CMS proposed and final rule on Medicare Part D; H.R. 4709- Ensuring Patient Access and Effective Drug Enforcement Act of 2014;S.2862 - Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014; H.R. 4190- To Amend Title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services; FDAs action on and enforcement of Public Law No: 113-54; H.R.4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014; H.R.4437 - Generic Drug Pricing Fairness Act; S. 1493 - Medicare Efficient Drug Dispensing Act of 2013; Generic Drug Pricing Spikes; The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013; H.R..4435 National Defense Authorization Act for Fiscal Year 2015 (Tricare Provisions); S. 2410 National Defense Authorization Act for Fiscal Year 2015 (Tricare Provisions); Perscription Drug Abuse and Diversion; H.Con.Res 25: Establishing the budget for the United States government for Fiscal Year 2014 and setting forth appropriate budgetary levels for Fiscal Year 2015 through 2023; S.Con.Res 8: An original concurrent resolution setting forth the Congressional budget for the United States Government for Fiscal Year 2014, revising the appropriate budgetary levels for Fiscal year 2013, and setting forth the appropriate budgetary levels for Fiscal Years 2015 through 2023.
Client expense: $530,000 · Firm income: Not reported
2014 · third_quarter · Pharmacy
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Client expense: $500,000 · Firm income: Not reported
2014 · third_quarter · Medicare/Medicaid
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Client expense: $500,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · second_quarter · Medicare/Medicaid
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Client expense: $550,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · second_quarter · Pharmacy
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Client expense: $550,000 · Firm income: Not reported
2014 · second_quarter · Health Issues
Federal policy regarding Public Law 113-54, the Drug Quality and Security Act; FDA proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; Proposed FDA rule, "Electronic Distribution of Prescribing Information for Human Prescription Drugs Including BiologicalProducts," RIN: 0910-AG18, provisions relating to the use of electronic package inserts for human pharmaceuticals and biologics; Implementations of Biosimilars in the Affordable Care Act (ACA), Biosimilar Naming, Implementation of FDASIA and Generic Drug User Fee Act; The Generic Drug Pricing Transparency Act, H.R. 4437; Risk Evaluation Mitigation Strategies, Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing
Client expense: $260,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Tariff (miscellaneous tariff bills)
House Tariffs Bills: H.R. 4435, H.R. 4436, H.R. 4437, H.R. 4438, H.R. 4473, H.R. 4474, H.R. 4475, H.R. 4476. H.R. 4477, H.R. 4478, H.R. 4479, H.R. 4506, H.R. 4507, H.R. 4508, H.R. 4509, H.R. 4510, H.R. 4511, H.R. 4512, H.R. 4513, H.R. 4514, H.R. 4515, H.R. 4516, H.R. 4517, H.R. 4518, H.R. 4519, H.R. 4520, H.R. 4701, H.R. 4702, H.R. 4703, H.R. 4704, H.R. 4705, H.R. 4706, H.R. 4707, H.R. 4708, H.R. 4741, H.R. 4742, H.R. 4743, H.R. 4744, H.R. 4745, H.R. 5504, H.R. 5505, H.R. 5506, H.R. 5507Senate Tariff Bills: S. 2596, S. 2595, S. 2594, S. 2593, S. 2525, S. 2519, S. 2524, S. 2522, S. 2633, S. 2626, S. 2629, S. 2632, S. 2907, S. 2597, S. 2908, S. 3138, S.2955, S. 2628, S. 2618, S. 3098, S. 2950, S. 3099, S. 2631, S. 2906, S. 2905, S. 2951, S.2523, S. 2521, S. 2619, S. 2627, S. 2624, S. 2630, S. 2625, S. 3139, S. 2598, S.2960
Client expense: $300,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2014 · second_quarter · Pharmacy
S.644, Preventing Abuse of Cough Treatments Act of 2013 S. 621, Safe Prescribing Act of 2013 H.R. 1285, Safe Prescribing Act of 2013 H.R. 1919 Safeguarding America's Pharmaceuticals Act of 2013 S 959, Pharmaceutical Compounding Quality and Accountability Act S 1277, Combating Prescription Drug Abuse Act S.957, Drug Supply Chain Security Act H.R.3204 - Drug Quality and Security Act H.R. 4437 - Generic Drug Pricing Fairness Act
Client expense: $640,000 · Firm income: Not reported
2014 · second_quarter · Pharmacy
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Client expense: $550,000 · Firm income: Not reported
2014 · second_quarter · Medicare/Medicaid
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)
Client expense: $550,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · second_quarter · Pharmacy
S.644- The Preventing Abuse of Cough Treatments of Acts of 2013; H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; H.R. 1188- The Preserving of Hometown Independent Pharmacies Act of 2013; CMS proposed rule on Medicare Part D; H.R. 4709- Ensuring Patient Access and Effective Drug Enforcement Act of 2014;H.R. 4190- To Amend Title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services; FDAs action on and enforcement of Public Law No: 113-54; H.R.4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014; H.R.4437 - Generic Drug Pricing Fairness Act; S. 1493 - Medicare Efficient Drug Dispensing Act of 2013
Client expense: $450,000 · Firm income: Not reported
2014 · first_quarter · Medicare/Medicaid
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare regulatory/legislative proposals to impede audit, mail order and preferred network restrictions.S. 867, Medicare Prescription Drug Integrity and And Transparency Act of 2013. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc). Issues regarding Maximum Allowable Cost (HR 4437)
Client expense: $650,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · first_quarter · Pharmacy
S.644, Preventing Abuse of Cough Treatments Act of 2013 S. 621, Safe Prescribing Act of 2013 H.R. 1285, Safe Prescribing Act of 2013 H.R. 1919 Safeguarding America's Pharmaceuticals Act of 2013S 959, Pharmaceutical Compounding Quality and Accountability Act S 1277, Combating Prescription Drug Abuse Act S.957, Drug Supply Chain Security Act H.R.3204 - Drug Quality and Security Act H.R. 4437 - Generic Drug Pricing Fairness Act
Client expense: $740,000 · Firm income: Not reported
2014 · first_quarter · Tariff (miscellaneous tariff bills)
House Tariffs Bills: H.R. 4435, H.R. 4436, H.R. 4437, H.R. 4438, H.R. 4473, H.R. 4474, H.R. 4475, H.R. 4476. H.R. 4477, H.R. 4478, H.R. 4479, H.R. 4506, H.R. 4507, H.R. 4508, H.R. 4509, H.R. 4510, H.R. 4511, H.R. 4512, H.R. 4513, H.R. 4514, H.R. 4515, H.R. 4516, H.R. 4517, H.R. 4518, H.R. 4519, H.R. 4520, H.R. 4701, H.R. 4702, H.R. 4703, H.R. 4704, H.R. 4705, H.R. 4706, H.R. 4707, H.R. 4708, H.R. 4741, H.R. 4742, H.R. 4743, H.R. 4744, H.R. 4745, H.R. 5504, H.R. 5505, H.R. 5506, H.R. 5507Senate Tariff Bills: S. 2596, S. 2595, S. 2594, S. 2593, S. 2525, S. 2519, S. 2524, S. 2522, S. 2633, S. 2626, S. 2629, S. 2632, S. 2907, S. 2597, S. 2908, S. 3138, S.2955, S. 2628, S. 2618, S. 3098, S. 2950, S. 3099, S. 2631, S. 2906, S. 2905, S. 2951, S.2523, S. 2521, S. 2619, S. 2627, S. 2624, S. 2630, S. 2625, S. 3139, S. 2598, S.2960
Client expense: $350,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
2013 · fourth_quarter · Tariff (miscellaneous tariff bills)
House Tariffs Bills: H.R. 4435, H.R. 4436, H.R. 4437, H.R. 4438, H.R. 4473, H.R. 4474, H.R. 4475, H.R. 4476. H.R. 4477, H.R. 4478, H.R. 4479, H.R. 4506, H.R. 4507, H.R. 4508, H.R. 4509, H.R. 4510, H.R. 4511, H.R. 4512, H.R. 4513, H.R. 4514, H.R. 4515, H.R. 4516, H.R. 4517, H.R. 4518, H.R. 4519, H.R. 4520, H.R. 4701, H.R. 4702, H.R. 4703, H.R. 4704, H.R. 4705, H.R. 4706, H.R. 4707, H.R. 4708, H.R. 4741, H.R. 4742, H.R. 4743, H.R. 4744, H.R. 4745, H.R. 5504, H.R. 5505, H.R. 5506, H.R. 5507Senate Tariff Bills: S. 2596, S. 2595, S. 2594, S. 2593, S. 2525, S. 2519, S. 2524, S. 2522, S. 2633, S. 2626, S. 2629, S. 2632, S. 2907, S. 2597, S. 2908, S. 3138, S.2955, S. 2628, S. 2618, S. 3098, S. 2950, S. 3099, S. 2631, S. 2906, S. 2905, S. 2951, S.2523, S. 2521, S. 2619, S. 2627, S. 2624, S. 2630, S. 2625, S. 3139, S. 2598, S.2960
Client expense: $300,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
2013 · third_quarter · Tariff (miscellaneous tariff bills)
House Tariffs Bills: H.R. 4435, H.R. 4436, H.R. 4437, H.R. 4438, H.R. 4473, H.R. 4474, H.R. 4475, H.R. 4476. H.R. 4477, H.R. 4478, H.R. 4479, H.R. 4506, H.R. 4507, H.R. 4508, H.R. 4509, H.R. 4510, H.R. 4511, H.R. 4512, H.R. 4513, H.R. 4514, H.R. 4515, H.R. 4516, H.R. 4517, H.R. 4518, H.R. 4519, H.R. 4520, H.R. 4701, H.R. 4702, H.R. 4703, H.R. 4704, H.R. 4705, H.R. 4706, H.R. 4707, H.R. 4708, H.R. 4741, H.R. 4742, H.R. 4743, H.R. 4744, H.R. 4745, H.R. 5504, H.R. 5505, H.R. 5506, H.R. 5507enate Tariff Bills: S. 2596, S. 2595, S. 2594, S. 2593, S. 2525, S. 2519, S. 2524, S. 2522, S. 2633, S. 2626, S. 2629, S. 2632, S. 2907, S. 2597, S. 2908, S. 3138, S.2955, S. 2628, S. 2618, S. 3098, S. 2950, S. 3099, S. 2631, S. 2906, S. 2905, S. 2951, S.2523, S. 2521, S. 2619, S. 2627, S. 2624, S. 2630, S. 2625, S. 3139, S. 2598, S.2960
Client expense: $390,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
2013 · second_quarter · Tariff (miscellaneous tariff bills)
House Tariffs Bills: H.R. 4435, H.R. 4436, H.R. 4437, H.R. 4438, H.R. 4473, H.R. 4474, H.R. 4475, H.R. 4476. H.R. 4477, H.R. 4478, H.R. 4479, H.R. 4506, H.R. 4507, H.R. 4508, H.R. 4509, H.R. 4510, H.R. 4511, H.R. 4512, H.R. 4513, H.R. 4514, H.R. 4515, H.R. 4516, H.R. 4517, H.R. 4518, H.R. 4519, H.R. 4520, H.R. 4701, H.R. 4702, H.R. 4703, H.R. 4704, H.R. 4705, H.R. 4706, H.R. 4707, H.R. 4708, H.R. 4741, H.R. 4742, H.R. 4743, H.R. 4744, H.R. 4745, H.R. 5504, H.R. 5505, H.R. 5506, H.R. 5507Senate Tariff Bills: S. 2596, S. 2595, S. 2594, S. 2593, S. 2525, S. 2519, S. 2524, S. 2522, S. 2633, S. 2626, S. 2629, S. 2632, S. 2907, S. 2597, S. 2908, S. 3138, S.2955, S. 2628, S. 2618, S. 3098, S. 2950, S. 3099, S. 2631, S. 2906, S. 2905, S. 2951, S.2523, S. 2521, S. 2619, S. 2627, S. 2624, S. 2630, S. 2625, S. 3139, S. 2598, S.2960
Client expense: $360,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
2013 · first_quarter · Tariff (miscellaneous tariff bills)
House Tariffs Bills: H.R. 4435, H.R. 4436, H.R. 4437, H.R. 4438, H.R. 4473, H.R. 4474, H.R. 4475, H.R. 4476. H.R. 4477, H.R. 4478, H.R. 4479, H.R. 4506, H.R. 4507, H.R. 4508, H.R. 4509, H.R. 4510, H.R. 4511, H.R. 4512, H.R. 4513, H.R. 4514, H.R. 4515, H.R. 4516, H.R. 4517, H.R. 4518, H.R. 4519, H.R. 4520, H.R. 4701, H.R. 4702, H.R. 4703, H.R. 4704, H.R. 4705, H.R. 4706, H.R. 4707, H.R. 4708, H.R. 4741, H.R. 4742, H.R. 4743, H.R. 4744, H.R. 4745, H.R. 5504, H.R. 5505, H.R. 5506, H.R. 5507Senate Tariff Bills: S. 2596, S. 2595, S. 2594, S. 2593, S. 2525, S. 2519, S. 2524, S. 2522, S. 2633, S. 2626, S. 2629, S. 2632, S. 2907, S. 2597, S. 2908, S. 3138, S.2955, S. 2628, S. 2618, S. 3098, S. 2950, S. 3099, S. 2631, S. 2906, S. 2905, S. 2951, S.2523, S. 2521, S. 2619, S. 2627, S. 2624, S. 2630, S. 2625, S. 3139, S. 2598, S.2960
Client expense: $420,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
| Republican |
| AK |
| Eric A. "Rick" Crawford | Republican | AR |
| Jeff Fortenberry | Republican | NE |
| Joe Barton | Republican | TX |
| John J. Duncan, Jr. | Republican | TN |
| Lou Barletta | Republican | PA |
| Mike Coffman | Republican | CO |
| Richard L. Hanna | Republican | NY |
| Roger Williams | Republican | TX |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Steve Southerland II | Republican | FL |
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE